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Migraine is the most common type of chronic episodic headache. Several population-based family studies have
suggested a strong genetic predisposition to migraine, especially migraine with aura (MA). Although several sus-
ceptibility loci have been identified, none of the numerous studies performed to date have led to the identification
of a gene responsible for the more common forms of migraine. GABA-A receptors and their modulator sites seem
to be involved in the pathophysiological events that underlie migraine. We report on clinical and molecular data
from a total of 10 families with MA, in which MA segregates as an autosomal dominant trait and presents with
homogeneous clinical features. After excluding linkage with the known candidate loci, we used a functional candidate
approach and genotyped these families with markers from the 15q11-q13 genomic region, which contains the genes
encoding GABA-A receptor subunits. Evidence of linkage was obtained with a parametric two-point linkage analysis
(maximum LOD score of 5.56 at a recombination fraction of 0.001 for marker GABRB3) and was supported by
multipoint analysis (maximum LOD score of 6.54 between markers D15S113 and D15S1019). The critical region
spanned 3.6 Mb. These results provide the basis for further investigation of the hypothesized relationship between
a GABA-A receptor dysfunction and migraine.
Migraine is the most common type of chronic episodic
headache, affecting 11% of the general population of
Western Europe and the United States (Goadsby et al.
2002). Up to 31% of migraine patients have an aura
consisting of transient (usually !60 min in duration) neu-
rological symptoms, whereas 5% have an aura without
headache (Goadsby et al. 2002). On the basis of clinical
manifestations, two types of migraine can be distin-
guished: migraine with aura (MA) and migraine without
aura (Rasmussen and Olesen 1992).
Several population-based family studies have sug-
gested a strong genetic predisposition to migraine, es-
pecially to MA (Russel and Olesen 1995; Ziegler et al.
1998), although the mode of inheritance remains un-
clear. Most likely, the two types of migraine are inherited
as multifactorial traits, with the exception of a few fam-
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ilies that display an autosomal dominant pattern of in-
heritance (Russel 2001). In any case, the genetic factors
are likely to act by determining a constitutional migraine
threshold modulated by external and internal triggers
(Pietrobon and Striessnig 2003). Although several sus-
ceptibility loci have been identified—on chromosomes
1q (MGR6 [MIM 607516]) (Ducros et al. 1997; Gard-
ner et al. 1997), 4q24-q28 (MGR1 [MIM 157300])
(Wessman et al. 2002), Xq24-q28 (MGR2 [MIM
300125]) (Nyholt et al. 2000), 19p13 (MGR5 [MIM
607508]) (Jones et al. 2001), and 14q21-q22 (MGR4
[MIM 607501]) (Soragna et al. 2003)—none of the nu-
merous studies performed to date have led to the iden-
tification of a gene responsible for the most common
forms of migraine. The only exception is familial hemi-
plegic migraine (MIM 141500), a rare autosomal dom-
inant subtype of migraine (Joutel et al. 1993) that is
caused by mutations in a gene on chromosome 19 en-
coding a calcium-channel alpha subunit (CACNA1A
[MIM 601011]) (Ophoff et al. 1996).
Little progress has been made toward understanding
the neurobiology of migraine. Activation of the trige-
minovascular system is thought to be responsible for the
Figure 1 Haplotypes and pedigrees of the five families with MA in linkage with the 15q11-q13 genomic region. The gray shading of the
symbol representing individual III-12 of family 2 indicates an MA-like phenotype (see text for discussion).
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Table 1
Clinical Features of Patients
FAMILY AND
PATIENT SEX
AGE
(years) PRESENCE OF FEATUREa
HEADACHE
SIDEb
HIGHEST
ATTACK
FREQUENCY
At
Study
At
Onset
Visual
Disturbance
Language
Disturbance
Sensory/Motor
Disturbance Confusion Ataxia Dizziness
1:
III-11 M 17 13    L 10/mo
III-13 F 20 12  R-L alternating 2–3/mo
II-4 F 43 10    R 3–4/mo
II-5 F 45 8  R-L alternating 1–2/mo
II-7 M 48 9   R-L alternating 1–2/mo
II-8 M 50 8  R-L alternating 2/mo
I-1 F 80 !18     R-L alternating 2/mo
2:
III-11 M 13 13  L 2/year
II-4 F 46 8    L 2–3/mo
II-5 F 48 7  R-L alternating 2/mo
II-6 F 50 8  R-L alternating 1–2/mo
II-7 F 53 9  R-L alternating 2/mo
II-10 M 59 10   R-L alternating 1–2/mo
II-8 F 55 7  R-L alternating 2/mo
3:
III-5 F 16 10  Bilateral Daily
I-1 M 75 !18  Bilateral 4/mo
II-4 F 55 !18  Bilateral 3–4/year
4:
IV-8 M 15 14    Bilateral 5–6/year
III-7 F 35 12  R-L alternating 2–3/mo
II-4 F 38 10   R-L alternating 2/mo
5:
III-7 M 10 6    Bilateral 2–3/year
II-4 F 28 8  R-L alternating 2/mo
II-5 F 35 7  R-L alternating 2–3/mo
I-1 F 50 12  R-L alternating 1/mo
a A plus sign () indicates presence of clinical feature.
b Rp right; L p left.
pain, whereas cortical spreading depression (CSD) seems
to underlie the aura symptoms (Pietrobon and Striessnig
2003). In a recent study, Bolay et al. (2002) showed that
CSD activates trigeminal afferents that cause inflam-
mation of the pain-sensitive meninges, generating a
headache. These data point to CSD as a critical event
in the mechanisms of MA and support the emerging
notion that CSD is a valid therapeutic target (Iadecola
2002).
An increase in excitability could explain the predis-
position of the brain to episodes of CSD (Parsons 1998).
The mechanisms that underlie the cortical excitability
and its periodicity remain unclear. A possible cause is
an abnormal release of excitatory neurotransmitters or,
alternatively, a reduced intracortical inhibition (Pietro-
bon and Striessnig 2003). With regard to the latter al-
ternative, several studies demonstrate a very likely in-
volvement of GABAergic circuits through deficient
intracortical inhibitory processes, especially in patients
with MA (Aurora et al. 1998; Palmer et al. 2000).
Moreover, it is currently thought that the neuronal
mechanisms underlying headache may work similarly in
healthy individuals and individuals with migraines, but,
because of central neuronal hyperexcitability in patients
with migraine, headache is more easily triggered in these
individuals. In recent years, the concept of migraine as
a result of CNS hyperexcitability has led to the use of
GABAergic anticonvulsivant medications as the first line
of therapy for prevention of migraine (Silberstein 2004).
In particular, GABA-A receptors and their modulator
sites seem to be involved in the pathophysiological events
that underlie migraine, mainly at the trigeminovascular-
complex level (Cutrer and Moskowitz 1996; Storer et
al. 2001, 2004).
Therefore, we hypothesized that genes encoding
GABA-A receptor subunits should be good candidate
genes and performed linkage analysis in 10 families with
MA by use of markers from the 15q11-q13 genomic
region, which harbors three genes encoding three GABA-
A receptor subunits. The genotyping of 10 families with
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Figure 2 Graphic representation of the results of multipoint linkage analysis
MA by use of microsatellite markers from candidate
regions identified elsewhere (19p13, 1q21-q23, 1q31,
4q24, and 14q24) showed several recombinations in af-
fected individuals. Multipoint analysis did not support
linkage with these loci, clearly showing negative LOD
score values (data not shown).
On the contrary, microsatellite analysis with markers
from the 15q11-q13 region showed no recombinants in
affected individuals from five families with MA. In the
other five families with MA, we did not observe cose-
gregation of haplotypes with the disease. Haplotypes
and pedigrees of the five linked families are shown in
figure 1. Clinical data from 25 affected members of these
families are reported in table 1. In a linkage analysis (by
use of LINKAGE 5.1 software [Lathrop et al. 1984]),
the highest two-point values were obtained with markers
GABRB3 (Zmax p 5.56 at vmax p 0.001) and D15S97
(Zmax p 5.31 at vmax p 0.001), under the assumption
of 100% penetrance (table 2). The two-point score val-
ues, under the assumption of 80% penetrance, are
shown in table 3. The highest Zmax values for the same
two markers were 5 and 4.75, respectively, at vmax p
0.001. Multipoint linkage analysis (by use of SIMWALK
2.89 software [Sobel and Lange 1996]) provided strong
evidence of linkage between markers D15S113 and
D15S1019, with a maximum LOD score of 6.54 for
marker GABRA5 (fig. 2), confirming the results of the
two-point analysis. The genomic region within proximal
and distal recombinants spanned 3.6 Mb (fig. 3).
According to the University of California–Santa Cruz
(UCSC) database, this critical region harbors the follow-
ing genes: GABRB3 (MIM 137192; GenBank accession
number NM_021912), GABRA5 (MIM 137142),
GABRG3 (MIM 600233), OCA2 (MIM 203200),
HERC2 (MIM 605837), APB2, and NDNL2 (MIM
608243).
We focused on the three genes encoding GABA-A re-
ceptor subunits and sequenced the coding region in af-
fected and unaffected individuals from the five linked fam-
ilies. We did not detect any significant mutation; rather,
we detected a polymorphism, C75T, in the first exon of
the GABRB3 gene in all affected members of family 1.
We detected a significant linkage between the MA phe-
notype and markers within the 15q11-q13 genomic re-
gion, thus providing strong evidence of the existence of
an MA susceptibility locus on the proximal chromosome
15q. Evidence of linkage was obtained by parametric
two-point linkage analysis and was supported by mul-
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Table 2
Two-Point LOD Scores under the Assumption of 100% Penetrance
MARKER
LOD AT v p
vmax Zmax.001 .01 .05 .1 .2 .3 .4
D15S817 1.95 .96 .30 .06 .11 .17 .14 .3 .17
D15S128 1.73 2.65 3.02 2.88 2.27 1.47 .59 .05 3.02
D15S10 .78 1.57 1.98 1.93 1.50 .93 .35 .05 1.98
D15S986 .41 1.36 2.40 2.56 2.23 1.58 .78 .1 2.56
D15S113 .05 1.72 2.76 2.92 2.56 1.84 .91 .1 2.92
GABRB3 5.56 5.47 5.04 4.48 3.32 2.10 .87 .001 5.56
D15S97 5.31 5.22 4.80 4.26 3.12 1.94 .78 .001 5.31
GABRA5 3.16 4.07 4.34 4.08 3.20 2.10 .92 .05 4.34
D15S975 .74 1.67 2.02 1.88 1.31 .80 .36 .05 2.02
D15S1019 4.48 4.41 4.07 3.63 2.71 1.71 .69 .001 4.48
D15S1010 7.44 3.59 .88 .13 .75 .71 .35 .2 .75
D15S971 13.62 7.64 3.59 1.99 .69 .22 .06 .4 .06
D15S118 11.80 5.88 2.02 .65 .26 .37 .16 .3 .37
D15S1012 14.11 8.14 4.08 2.46 1.05 .43 .14 .4 .14
NOTE.—The highest values for each marker are shown in bold.
Figure 3 Map of the critical region for MA. The microsatellite markers used for genotyping are indicated at top. Distances between
markers are as given in the UCSC database. Known genes are indicated at bottom. The critical region between markers D15S113 and D15S1019
is boxed.
tipoint analysis (Lander and Kruglyak 1995). We could
use this type of analysis because, in the families we stud-
ied, MA segregates as an autosomal dominant trait and
presents with homogeneous clinical features. The only
exception was individual III-12 in family 2 (see fig. 1),
who suffered from a single hemiplegic attack, unprec-
edented in her family, resembling a form of sporadic
hemiplegic migraine (SHM), which is considered to be
a separate diagnostic entity from typical MA (Headache
Classification Subcommittee of the International Head-
ache Society 2004). This patient did not share the af-
fected haplotype, which confirms that she is affected by
a different condition—that is, SHM. Alternatively, her
condition can be interpreted as a phenocopy. The pres-
ence of phenocopies is not an uncommon phenomenon
in families with MA (Soragna et al. 2003).
As illustrated in figure 3, the MA critical region spans
3.6 Mb and is defined by the proximal marker D15S113
and the distal marker D15S1019. A number of genes
map to this interval. Among these, GABRB3, GABRG3,
and GABRA5—encoding b3, g3, and a5 GABA-A re-
ceptor subunits, respectively—can be considered the best
candidates. Two imprinted genes, maternally expressed,
are located in the proximity of the centromeric boundary
of the critical region: UBE3A (MIM 601623) (Matsuura
et al. 1997) and the more closely located ATP10A (MIM
605855) (Meguro et al. 2001). Since we observe an ex-
cess of maternal transmission of the disease in these fam-
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Table 3
Two-Point LOD Scores under the Assumption of 80% Penetrance
MARKER
LOD AT v p
vmax Zmax.001 .01 .05 .1 .2 .3 .4
D15S817 1.62 .87 .27 .05 .11 .16 .13 .3 .16
D15S128 1.55 2.35 2.72 2.62 2.07 1.34 .54 .05 2.72
D15S10 .35 1.13 1.57 1.55 1.21 .74 .27 .05 1.57
D15S986 .64 .92 1.96 2.16 1.92 1.37 .68 .1 2.16
D15S113 .28 1.36 2.40 2.58 2.28 1.64 .80 .1 2.58
GABRB3 5.00 4.91 4.52 4.01 2.95 1.85 .76 .001 5.00
D15S97 4.75 4.67 4.28 3.78 2.75 1.69 .67 .001 4.75
GABRA5 2.83 3.61 3.89 3.67 2.87 1.88 .81 .05 3.89
D15S975 2.57 2.51 2.25 1.90 1.19 .65 .27 .05 2.57
D15S1019 4.14 4.07 3.75 3.34 2.48 1.56 .62 .001 4.14
D15S1010 6.76 3.69 1.11 .11 .55 .56 .27 .2 .56
D15S971 8.62 5.40 2.68 1.53 .56 .19 .05 .4 .05
D15S118 9.44 4.97 1.78 .61 .17 .27 .11 .3 .27
D15S1012 10.41 7.01 3.71 2.31 1.05 .47 .16 .4 .16
NOTE.—The highest values for each marker are shown in bold.
ilies, we cannot rule out the existence of an imprinting
effect on the MA phenotype, even though the sequencing
of the ATP10A gene did not detect any mutation (data
not shown). In addition, we performed a mutational
analysis of the coding sequences of three GABA-A re-
ceptor genes in at least one affected member from each
family, but we did not detect any significant sequence
variation. Only a single polymorphism (C75T) in the
first exon of GABRB3 was found in family 1. Even
though we failed to detect significant mutations, we can-
not rule out the possibility that dysfunctional activity of
these GABA receptor subunits is due either to poly-
morphisms, such as C75T, that have functional effect or
to mutations in noncoding regulatory sequences.
Given the ubiquitous expression and the vital function
of the GABA-A receptors, which ligate a neurotrans-
mitter widely distributed throughout the CNS, we ex-
pected to find not clear pathogenetic mutations in pa-
tients with MA but, rather, variants with a mild effect
on protein function. However, we cannot exclude the
possibility that mutations in regulatory sequences lo-
cated outside the coding region might have strong bio-
chemical effects, similar to what would be expected for
an autosomal dominant condition. In addition, there are
several lines of evidence suggesting that GABAergic
drugs modulate biochemical and physiological events in-
volved in the pathophysiology of migraine, particularly
via GABA-A receptor–mediated mechanisms.
It has been proposed elsewhere that an increase in
inhibitor GABAergic neurotransmission may suppress
the abnormal cortical events underlying the migraine
aura (Cutrer et al. 1997). The GABAergic migraine pro-
phylactic drugs may restore a normal cortical inhibitory
potential by elevating cortical threshold for spreading
depression propagation in patients with migraines (Pal-
mer et al. 2000). Valproic acid blocks neurogenic in-
flammation within the meninges via GABA-A receptor–
mediated mechanisms (Cutrer et al. 1997). Other studies
underline the specific importance of GABA-A receptors
in modulating trigeminovascular nociceptive neuro-
transmission (Cutrer et al. 1995, 1997; Storer et al.
2001, 2004). It is also very interesting that an anaesthetic
agent, propofol, acting in a well-documented manner at
GABA-A receptor subtypes, may represent a rapid and
highly effective form of abortive headache treatment
(Krusz et al. 2000).
Our study also confirmed the role of GABAergic med-
ications. During the period of clinical observation, in-
dividuals II-7 and II-8 of family 1 needed prophylactic
therapy for the worsening of migraine. Within 2 wk of
administration, sodium valproate completely abolished
their headaches.
This result further supports the link between the pa-
tients’ conditions, drug response, and genetic findings in
the families we studied. In conclusion, our results may
provide the basis for further investigation of the hy-
pothesized relationship between a possible GABA-A re-
ceptor dysfunction and migraine (Cutrer and Moskowitz
1996).
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GABRB3, GABRA5, OCA2, HERC2, NDNL2, UBE3A,
and ATP10A)
UCSC, http://www.genome.ucsc.edu
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